24/7 Market News Snapshot 15 April, 2025 – NLS Pharmaceutics Ltd. Ordinary Shares (NASDAQ:NLSP)

April 15, 2025

DENVER, Colo., 15 April, 2025 (www.247marketnews.com) – (NASDAQ:NLSP) are discussed in this article.
NLS Pharmaceutics Ltd. is currently trading at $1.500, reflecting a significant rise of 3.45% in pre-market activity, building on a previous close of $1.450. This surge signals robust bullish momentum as the stock market opens, supported by a substantial trading volume of 1.08 million shares, indicating heightened investor interest that may be influenced by favorable news or market sentiment. The stock has surpassed key resistance levels, which may suggest further upward potential, particularly if moving averages continue to diverge positively, warranting close monitoring from investors given the implications for short-term price movements and overall market confidence.

In parallel, NLS Pharmaceutics has recently disclosed promising preclinical outcomes from Study KO-943, demonstrating the potential of Mazindol as an innovative, non-opioid treatment for fentanyl use disorder. Conducted in collaboration with Key-Obs SAS, the study illustrated that Mazindol significantly diminished fentanyl-induced conditioned place preference in mice, highlighting its capability to address the escalating opioid crisis, particularly as fentanyl-related overdoses continue to rise in prominence.

Amid increasing demands for effective non-opioid alternatives, the market for substance use disorder treatments is projected to grow substantially, underscoring the urgent necessity for groundbreaking solutions. Mazindol’s unique mechanism of action targets multiple receptors, alleviating both the adverse effects linked to opioid withdrawal and the reward pathways associated with addiction. Engaging with various receptors, Mazindol may provide a safer alternative to conventional opioid substitution therapies.

Dr. Eric Konofal, Chief Scientific Officer of NLS Pharmaceutics, remarked on the findings, emphasizing Mazindol’s unprecedented multi-target profile, which could potentially transform treatment strategies in the battle against the opioid epidemic. Furthermore, NLS Pharmaceutics is strategically poised for growth following a recent equity raise and a merger agreement with Kadimastem Ltd., enhancing its commitment to addressing significant healthcare challenges within the realm of central nervous system disorders. As developments unfold, the company’s contributions to addiction therapeutics could prove to be transformative.

Related news for (NLSP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.